This morning Khiron Life Sciences Corp (TSXV: KHRN) have announced that they have received the status of Strategic project of national interest by the government of Colombia. This certification allows Khiron to simplify the authorization process, reduce costs and accelerate the time to market of its services and products for the Colombian domestic market and for the export of finished products.
The Strategic project of national interest the certification was established to prioritize the development of specific projects / enterprises which are considered by the government to be able to significantly increase the national economy. This certification immediately simplifies and speeds up administration and the ability to process the execution of strategic projects in Colombia. As part of this plan, Khiron aims to register and introduce more than 4 SKUs in the Medical Cannabis category and at least 10 SKUs in the Consumer Packaged Goods category.
According to the official press release of the company, ‘Khiron is one of three companies to achieve this status, placing the company at the forefront of the industry in Colombia.. ‘
This morning it was also announced that PharmaCielo is receiving the same status.
Khiron shares last traded at 49.5c on the TSX Venture Exchange at the time of publication.
FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author was paid to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a buy or sell recommendation. Always do additional research and consult a professional before purchasing a title.
SmallCapSteve started blogging in the winter of 2009. During that time, it was able to spot many redeeming candidates and choose a variety of stocks that have generated returns in excess of 200%. Today, he consults with micro-capitalized companies assisting them with capital markets strategy and focuses on sectors such as cannabis, technology and junior mining.